New drug SH006 tested in patients with advanced solid tumors
NCT ID NCT07362264
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests the safety and tolerability of a new drug called SH006 in 50 adults with advanced solid tumors, including liver cancer. Participants receive SH006 every three weeks. The study aims to find the best dose for future trials and monitor side effects. It is not yet known if the drug can effectively fight cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SH006 injection
What this could lead to
If this trial shows the drug is safe and tolerable, it could lead to a recommended dose for larger studies testing whether SH006 can shrink tumors or slow cancer growth.
What could go wrong
This is a very early Phase 1 trial with only 50 people, so the main goal is safety, not effectiveness. The drug may not work against the cancer, and side effects could be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Nanjing Tianyinshan Hospital
Nanjing, Jiangsu, China